stockrow
Friday 6 November 2026
Export TARS’s income statement to Excel — free account
Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
68.81
1.29
+1.91%
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Revenue growth
Tarsus Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 September 2026 was 86.3%, down 60.4 percentage points from fiscal 2025 (146.7%). That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 146.7% | (801.91) |
| FY2024 | 948.6% | 981.04 |
| FY2023 | −32.4% | 22.31 |
| FY2022 | −54.7% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 63.9% | (5.49) |
| Jun 2026 | 69.4% | (37.46) |
| Mar 2026 | 106.9% | (21.52) |
| Dec 2025 | 128.4% | (18.29) |
| 13 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. | 86.3% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 14.8% |
| VRDN Viridian Therapeutics, Inc. compare | −62.8% |
| DNLI Denali Therapeutics Inc. compare | −93.4% |
| VKTX Viking Therapeutics, Inc. compare | — |
| TLX Telix Pharmaceuticals Limited compare | — |
| CELC Celcuity, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement